MAPK3 and cancer: In addition, simultaneous inhibition of mTOR and ERK1/2 could further increase the accumulation of ROS in tumor cells (Jasek-Gajda et al., 2020), suggesting a synergistic effect of combined mTOR and ERK1/2 inhibitors for cancer therapy.